FILTER
FILTERED INTERVIEW RESULTS
José M. Berges
CEO, GTM HOLDINGS
GTM is highly focused on M&A to grow its presence and capabilities in Latin America.
Jorge Buckup
PRESIDENT LATIN AMERICA, UNIVAR SOLUTIONS
Univar Solutions is expanding its business in the Latin America region through a series of acquisitions.
João Parolin
CEO, OXITENO
Chemical manufacturing company Oxiteno is exploting opportunities in the United States while maintaining an eye on economic recovery in Latin America.
Peter Staartjes
CEO, ANDINO HOLDINGS
Andino Holdings, which provides logistics services for the chemicals industry, is increasingly focused on the opportunities afforded by digitalization.
Martin Sack
MANAGING DIRECTOR, LESCHACO MEXICANA
Leschaco Mexicana provides a comprehensive range of logistics services to the chemicals industry and other verticals.
Martín Toscano, Miguel Ángel Delgado, Federico Téllez
MANAGING DIRECTOR, BUSINESS DIRECTOR RE - HIGH PERFORMANCE POLYMERS & BUSINESS DIRECTOR CYPLUS, EVONIK INDUSTRIES DE MÉXICO
Evonik is one of the world's leading specialty chemicals companies.
Stefan Lepecki
CEO, BRASKEM IDESA
Braskem Idesa was formed by Braskem S.A. (Brazil), the largest producer of thermoplastic resins in America and Grupo Idesa (Mexico), a leader in petrochemicals.
Eugenio Manzano
EXECUTIVE DIRECTOR, POCHTECA
Pochteca offers a portfolio of over 7,300 industrial products to clients throughout Latin America.
Ricardo Diogo
DIRECTOR BUSINESS DEVELOPMENT, OILTANKING
A look at the liquids storage market in Latin America and its potential consolidation.
Matthias Vorbeck & Alejandro Gabrielli
GENERAL MANAGER & REGIONAL MANAGER, ANASTACIO OVERSEAS
The company continues expanding in Latin America capitalizing the synergies with the distribution business of Química Anastacio.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
